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Alison R. Evansd, Michael Karrand, José Luis Molinuevoe,f , Matthew Nortond and Alireza Atrig,h,∗
aShift Health, Toronto, ON, Canada
bDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
cUniversity of Exeter, Exeter, UK
dAlzheimer’s Research UK, Cambridge, UK
eBarcelonaβeta Brain Research Center, Barcelona, Spain
f Paqual Maragall Foundation, Barcelona, Spain
gBanner Sun Health Research Institute, Banner Health, Sun City, AZ, USA
hDepartment of Neurology, Center for Brain/Mind Medicine, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA, USA
Accepted 10 May 2019
Abstract. While it is generally understood that Alzheimer’s disease (AD) and related dementias (ADRD) is one of the costliest
diseases to society, there is widespread concern that researchers and policymakers are not comprehensively capturing and
describing the full scope and magnitude of the socioeconomic burden of ADRD. This review aimed to 1) catalogue the different
types of AD-related socioeconomic costs described in the literature; 2) assess the challenges and gaps of existing approaches
to measuring these costs; and 3) analyze and discuss the implications for stakeholders including policymakers, healthcare
systems, associations, advocacy groups, clinicians, and researchers looking to improve the ability to generate reliable data that
can guide evidence-based decision making. A centrally emergent theme from this review is that it is challenging to gauge the
true value of policies, programs, or interventions in the ADRD arena given the long-term, progressive nature of the disease,
its insidious socioeconomic impact beyond the patient and the formal healthcare system, and the complexities and current
deficiencies (in measures and real-world data) in accurately calculating the full costs to society. There is therefore an urgent
need for all stakeholders to establish a common understanding of the challenges in evaluating the full cost of ADRD and
define approaches that allow us to measure these costs more accurately, with a view to prioritizing evidence-based solutions
to mitigate this looming public health crisis.
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INTRODUCTION
Alzheimer’s disease (AD) and related dementias
(ADRD) are a major cause of disability and depen-
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dency among older adults worldwide [1], having a
significant impact not only on individuals but also
on their families, communities, and societies. In
2015, dementia costs were estimated at US$818 bil-
lion, equivalent to 1.1% of global gross domestic
product—a staggering cost that had grown by 35%
since 2010. By 2030, it is estimated that the global
cost of dementia could grow to US$2 trillion, which
could overwhelm health and social care systems [2].
While it is generally acknowledged that ADRD
is one of the costliest diseases to society [3, 4],
the burden is complex and has been difficult to
assess accurately due to myriad factors [2, 4, 5].
As patients require the support of multiple stake-
holders across the healthcare and social care sectors,
as well as from family members and friends, the
cost of care is not neatly captured by typical health-
care delivery systems. The impact on the quality
of life of both patients and their caregivers [6] is
not readily translated into monetary costs. While
our understanding of the mechanisms of AD and
related neurodegenerative diseases, co-morbidities,
and aging processes, that often combine to lead to
cognitive or behavioral decline, clinical symptoms
and cognitive impairment and dementia (CID), is
expanding, it still remains limited [7]. This limited
understanding, combined with the practical chal-
lenges that result in low rates of detection, diagnosis,
disclosure, and care [7] in patients with ADRD until
the middle and later stages of CID, results in a
potentially significant, but grievously understudied,
‘hidden’ cost associated with early ADRD. More-
over, considerable heterogeneity exists across cost of
illness studies with respect to the nature of the popu-
lations studied, terminologies and the methods used
[5, 8–11].
Concerns have recently been raised that
researchers and policymakers are not compre-
hensively capturing and describing the full scope
and magnitude of the socioeconomic burden of
ADRD and that additional research is needed to
better capture the value of care and costs of ADRD
[5, 6]. In the U.S., there also appears to be significant
gender and racial/ethnic disparities in prevalence,
access, and costs related to CID, with costs and care
burden being much higher in women and minorities,
particularly Blacks/African American [6, 12]. From
a public policy perspective, accurately assessing
the socioeconomic costs of ADRD is critical to
prioritizing effective, evidence-based policies,
and intervention and implementation strategies,
particularly given the potential arrival of high-cost
interventions, such as disease-modifying therapies,
whose cost-effectiveness may be difficult to ascer-
tain by conventional methods. Several reports have
recently discussed the challenges and limitations
in assessing the full costs of ADRD, with varying
degrees of scope and comprehensiveness [5, 13, 14].
This review aimed to 1) catalogue the differ-
ent types of ADRD-related socioeconomic costs
described in the literature; 2) assess the challenges
and gaps of existing approaches to measuring these
costs; and, 3) analyze and discuss the implications for
stakeholders including policymakers, healthcare sys-
tems, associations, advocacy groups, clinicians and
researchers looking to improve our ability to generate
reliable data that can guide evidence-based decision
making.
DEFINITIONS
Please see Table 1 for a glossary of abbreviations
used in this review. As many of the reports cited in
this review did not explicitly separate individuals with
AD from patients with other causes of CID (e.g., vas-
cular cognitive impairment and dementia, dementia
with Lewy bodies, frontotemporal dementias), and
with the recognition that the sporadic AD phenotype
in older individuals is often due to mixed patholo-
gies that include AD (e.g., AD+vascular-ischemic
brain injury pathologies; AD+Lewy body patholo-
gies) [15–18] the term ‘Alzheimer’s and related
dementias (ADRD)’, as employed in other reviews,
was used when presenting and discussing the costs of
diseases [14]. The terms ‘Alzheimer’s’ or ‘AD’ were
used when the data or discussion is relevant only to





Alzheimer’s Disease and Related Dementias (ADRD)
Cognitive Impairment and Dementia (CID)
Dementia Quality of Life (DEMQOL)
Emergency Department (ED)
EuroQol Five-Dimension Questionnaire (EQ-5D)
Health-Related Quality of Life (HRQOL)
Mild Cognitive Impairment (MCI)
Out of Pocket (OOP)
Quality of Life (QOL)
Quality of Life in Alzheimer’s Disease (QOL-AD)
Quality-Adjusted Life Year (QALY)
Resource Utilization in Dementia (RUD)
Zarit Burden Interview (ZBI)
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DIRECT COSTS
Direct costs have been described as goods and
services for which money is explicitly exchanged
[20]. In the context of ADRD, this is generally con-
sidered to include medical and social/non-medical
care costs for patients related to their illness [8,
21–28]. While the classification of medical and social
care costs can vary across countries, direct medi-
cal costs typically include elements such as medical
practitioner/allied health professional visits, hospital
care, medical treatments/medications, and special-
ized aids and equipment. Social care and non-medical
costs could include elements such as community
and social services (e.g., transportation, peer support,
and psychosocial interventions), private and publicly
funded home care, special accommodations (e.g.,
nursing homes), patient income and welfare support,
and household expenses (e.g., home modifications).
While it is recognized that caregivers can exhibit an
array of health issues (e.g., depression, weakened
immune system, and cardiovascular problems) asso-
ciated with the stresses of caring for patients with
ADRD [29–32], there is a lack of consensus in the
literature on how to categorize the direct costs asso-
ciated with caring for the caregiver. In this review,
both patient- and caregiver-related costs for which
money is explicitly exchanged are included under the
category of “Direct Costs”. Please see Box 1 for a
summary of key findings from this section.
Patients and caregivers: Measurement of direct costs
Direct medical and social/non-medical costs have
generally been measured using two approaches.
Several studies have relied on administrative data
drawn from centralized databases such as insur-
ance claims data or patient registries [14]. Others
have employed surveys or standardized question-
naires administered to patients and their caregivers to
measure self-reported resource utilization for patients
and caregivers (e.g., living accommodation, hospital-
izations, community care services); healthcare costs
are then estimated by multiplying unit costs of ser-
vices and products by recorded resource use [33].
Several instruments have been used to gather resource
use data, including Resource Utilization in Dementia
(RUD), Client Service Receipt Inventory, Resource
Use Inventory, cost diary, and informal care survey
[33, 34]. The RUD, and its short version, the RUD
Lite, are among the most, if not the most, commonly
used instrument for collecting resource use data in
Box 1: Direct Costs—Key Takeaways
• Direct costs in ADRD include both med-
ical (e.g., medication, hospitalization) and
social/non-medical (e.g., residential care)
costs for patients and caregivers.
• These costs have been measured using admin-
istrative data sets (e.g., insurance claims) or
standardized questionnaires (e.g., Resource
Utilization in Dementia Questionnaire) that
quantify self-reported resource use.
• Several challenges have been noted in mea-
suring direct costs in ADRD. For example,
medical insurance claims may not capture the
full direct costs of ADRD, such as household
out-of-pocket expenditures or the costs borne
by other insurers; moreover, self-reported
resource use is subjective and difficult to stan-
dardize.
• Despite these methodological challenges,
several studies have shown that the direct
patient costs of AD are substantial and
increase over time or with disease severity;
notably, direct costs may begin to accrue sev-
eral years prior to a dementia diagnosis.
ADRD [34]. The RUD was designed, over 20 years
ago, to be useful in different care settings, across
different countries and care systems, and provides
an informant-reported estimate of caregiving time
and related activities; support services received by
the patient (e.g., day care, meals on wheels, in-
home care), medications, and medical/health-related
visits (e.g., number of visits to general practitioner
or physiotherapist, emergency department [ED] and
hospitalizations). While numbers of visits to the ED
and nights spent in hospital in different wards are
reported by the informant and are counted in “units”
of utilization to be multiplied by a generic (mean)
unit costs per service, lack of verification of number,
nature, and extent of each service utilized represents
a major limitation in extrapolation of the actual costs
incurred.
Several additional challenges have been noted
in measuring direct costs in ADRD. In general,
ADRD, particularly early in its course, has been
under- or misdiagnosed or underreported [14], which
could lead to the under- or overestimation of costs
across studies [35–37]. Additionally, many studies
have applied variable and specific inclusion criteria
(e.g., availability of an informal caregiver, enrolled
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in memory clinics), which can potentially introduce
selection bias and challenges the validity of extrapo-
lating results to the general ADRD population [25, 26,
38]. Moreover, most patients in the dementia stages of
ADRD are elderly and typically suffer from comor-
bidities, such as cerebrovascular disease, albeit at a
higher rate compared to individuals without ADRD
[39, 40]. Most reports, however, do not distinguish
direct costs that are a consequence of ADRD symp-
toms from direct costs attributable to comorbidities.
Similarly, it has been challenging to ascribe caregiver
direct costs as a specific and unique consequence of
caregiving for an ADRD patient [25].
From a methodological standpoint, studies based
on medical insurance claims data may not capture
the full direct costs of ADRD, such as out-of-pocket
expenses (e.g., co-payments) borne by patients and
caregivers or the costs to other insurers (e.g., pen-
sion insurance paying for rehabilitation services) [14,
38]. While studies relying on surveys and question-
naires may capture a broader range of costs, these
are based on self-reported measures and might be
subject to inaccuracies [14, 26]. For example, it has
been shown that survey estimates tend to underesti-
mate healthcare utilization in the elderly population
[41], and this effect could be hypothesized to be even
potentially greater due to impairments in awareness,
insight, memory and cognition in individuals with
ADRD.
Commentary
Direct costs for patients begin to mount before
a diagnosis of ADRD
Using records from the Danish National Patient
Registry, increased healthcare costs were identified
in patients as early as 10 years prior to a diagno-
sis of ADRD [22]. Importantly, partners of patients
exhibited statistically significant increases in health-
care costs up to 2 years prior to diagnosis. Similarly,
other studies have found that healthcare costs increase
in both ADRD [42–44] and mild cognitive impair-
ment (MCI) [42] patients up to one-year prior to
diagnosis [44]. For example, Medicare expenditures
were 42% and 41% higher in ADRD and MCI
patients, respectively, compared to matched con-
trols one year prior to diagnosis. The propensity
of evidence supports that individuals with undiag-
nosed ADRD account for higher direct costs in the
years leading up to the ultimate recognition and
diagnosis of their cognitive impairment/dementia.
The driver of these costs relates to consequences of
unrecognized or unmanaged cognitive and behavioral
impairments and vulnerabilities in individuals with
undiagnosed ADRD that could include: 1) exacer-
bation of co-morbid conditions due to the patient’s
inability to properly manage their medical conditions
(that can lead to additional unnecessary testing, med-
ications, procedures, ED visits and hospitalizations);
2) diagnostic testing, medications, or procedures for
vague or unrecognized dementia-associated symp-
toms (e.g., depression, hearing loss, GI symptoms,
dizziness, anxiety, and sleep disturbances); 3) injuries
such as falls, motor vehicle accidents, and accidents
in the home precipitated by lack of planning, fore-
sight, insight, judgment, or cognitive abilities; and 4)
delirium [45], a major driver for ED visits and hos-
pitalizations, as well as in-hospital or post-operative
complication and morbidity.
Direct costs generally increase over time, driven
primarily by social care costs
Several longitudinal studies have shown that the
direct patient costs of AD increase over time or with
disease severity [24, 25, 27, 46] and are higher in
nursing home residents, compared to community-
dwelling patients [26, 47]. In community-dwelling
patients, the main driver appears to be patient social
care costs [24, 25], while direct medical costs for
patients and for caregivers do not differ according to
ADRD severity [24, 25, 46].
Out-of-pocket expenditures borne by ADRD
patients are high, exceed those of individuals
without ADRD, and are disproportionately
borne by women and minorities
Only a few studies, primarily based on US
populations, have conducted detailed analyses of
out-of-pocket expenditures in ADRD patients and
caregivers and the subsequent burden placed on
households and families [14]. For example, in a study
of Medicare beneficiaries in the US, out-of-pocket
(OOP) expenditures were higher in patients with
ADRD. Moreover, another study of Medicare ben-
eficiaries examined OOP spending during the last 5
years of life and found that OOP spending for patients
with dementia represented 32% of household wealth
compared to 11% for individuals without ADRD.
Moreover, the proportion of spending was higher for
African Americans, unmarried/widowed women, and
those with less than high school education [48]. Simi-
larly, out-of-pocket spending in caregivers of patients
with ADRD is approximately twice as high as those
for caregivers of individuals without ADRD [49].
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The Alzheimer’s Association has estimated that OOP
costs in 2018 could reach US$60 billion, or approxi-
mately 22% of the total costs of the disease [49].
INDIRECT COSTS
Indirect costs have generally been defined as a
“resource lost or invested for which no money is
exchanged” [20]. As noted by Alzheimer’s Disease
International [9, 50], there are two main sources of
indirect costs in ADRD. These include the costs of
informal care, arising from the unpaid inputs or the
productivity losses of informal caregivers, such as
families, friends, and others. In the U.S., it is esti-
mated that annually 18.5 billion hours of informal
care are provided by caregivers to individuals with
ADRD that translates to a contribution valuation of
US$234 billion per year [6]. Indirect costs may also
arise from productivity losses in patients due to work
impairment, sick leave, early retirement, or mortal-
ity. The estimated total lifetime cost of providing care
for an individual with dementia was US$350,174 in
2018 dollars and the costs associated with family care
make up 70% of lifetime dementia care costs [6, 51].
Furthermore, these estimates likely underestimate the
full impact of family caregivers’ health and work-
place productivity [6, 14]. Please see Box 2 for a
summary of key findings from this section.
Caregivers: Informal care costs
The impact of ADRD on informal caregiver
productivity has been assessed through various
approaches, including semi-quantitative surveys and
structured questionnaires aimed at caregivers. For
example, surveys conducted by Carers UK and
Employers for Carers [52] and the Alzheimer’s
Association [53] have asked series of ques-
tions on employment challenges. In other studies,
impairments have been assessed by quantifying
employment absenteeism and presenteeism [54, 55].
For instance, productivity impairments were assessed
using the Work Productivity and Activity Impairment
questionnaire in the Japan National Health and Well-
ness Surveys. While these types of studies do provide
insights into the employment challenges faced by
informal caregivers, they do not explicitly quantify
or value the associated costs.
Most reports that have quantified the cost of infor-
mal care rely on estimates of the time caregivers
spend in the provision of care. For instance, several
Box 2: Indirect Costs—Key Takeaways
• The main driver of indirect costs of ADRD is
the unpaid work of informal caregivers, such
as families and friends.
• The two most common approaches to quan-
tifying the cost of informal care rely on
estimates of the time caregivers spend in
the provision of care. The ‘replacement cost’
approach values informal care time using the
cost of an equivalent service bought in the
market, while the ‘opportunity cost (or human
capital)’ approach values informal care time
by estimating the loss of labor market income.
• There is no unified consensus in the literature
on the most appropriate approaches to esti-
mate indirect costs in ADRD, and the choice
of method and assumptions used can lead to
striking variability in cost estimates.
• Notwithstanding the variabilities in infor-
mal care cost estimates, several studies have
demonstrated a direct association between
costs and disease severity; interestingly, there
is evidence that the indirect costs of ADRD
may also be elevated many years prior to a
diagnosis of dementia.
• Emerging evidence suggests that informal
caregivers may be forced to cut back on sav-
ings and expenditures, thereby threatening the
financial security of households. This may
be further exacerbated by the fact that many
households will already be operating on fixed
retirement incomes.
population-based studies, such as GERAS observa-
tional study in France, Germany, and the UK, and the
European RightTimePlaceCare prospective cohort
study, have relied on the RUD questionnaire (see
‘Direct Costs’, above). This instrument assesses the
time caregivers spend on the provision of informal
care such as Activities of Daily Living and Instru-
mental Activities of Daily Living, while also asking
employed informal caregivers to state whether they
had reduced their work hours and to what degree.
Questionnaires such as the RUD and the RUD-Lite
form the foundation of two common approaches to
quantifying the value of informal care costs; namely,
the replacement cost approach [48, 56] and the oppor-
tunity cost approach (also referred to as the forgone
wages or human capital approach) [21, 57–59]. The
replacement cost approach values informal care time
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using the cost of an equivalent service bought in the
market, such as the cost of a formal (paid) caregiver.
The opportunity cost approach values informal care
time by estimating the loss of labor market income
using the caregiver’s expected market wage, such as
a national average wage.
The valuation (or costing) of informal care using
these approaches, however, is challenging in practice
[9, 50]. For example, it is often difficult to delimit time
spent by caregivers on different caregiving tasks, such
as basic supervision or support with activities of daily
living, which are self-reported and can occasionally
erroneously exceed 24 hours per day in totality. A
second major issue in the use of the opportunity cost
approach is determining the most appropriate alter-
native use of the caregiver’s time. While this is less
of a challenge for employed caregivers, where the
alternative is paid work, the valuation of time spent
by unemployed or retired caregivers is not straight-
forward and different strategies have been adopted.
For example, several studies segregate informal care-
givers by employment status, and have reduced the
opportunity cost of time for unemployed or retired
caregivers to about 25-35% of average labor force
wages, commonly referred to as the value of ‘leisure
time’ [23–25, 58]. In another study, unpaid ‘leisure
time’ in retired carers was valued based on aver-
age pension rates [60]. Another method has been to
scale down the labor force wage rate by multiply-
ing it by the rate of labor force participation in the
same demographic group [61]. Another challenge,
seldom discussed, is estimating the incremental or
differential costs to caregivers based on their sex or
relationship to the patient. For example, the major-
ity, approximately two-thirds, of informal caregivers
are women [6, 62–64], and a disproportionate burden
of caregiving has been demonstrated to fall on wives
and daughters compared to husbands and sons [65,
66]. The additional time that women invest in caring
for someone with dementia is thought to contribute
to higher levels of impaired mood, depression, and
impaired health compared to men [6].
Informal care has also been valued using at least
two other approaches, albeit less commonly than the
methods described above. The contingent valuation
approach [8, 20, 26, 67, 68] is rooted in welfare
economics and presents subjects with a hypothetical
market situation to obtain their monetary valuation
of a hypothetical change. In the case of ADRD,
this method consists in valuing informal care using
a ‘price’ the caregiver would be willing to pay to
reduce caregiving time by one hour, or, alternatively,
a willingness to accept a ‘payment’ to provide an
additional hour of care. It has been suggested that
such approaches can overcome the challenges asso-
ciated with the valuation of leisure time described
above and bring the added benefit of incorporating
caregivers’ preferences [68]. Finally, using a more
direct approach, one study relying on records from
the Danish National Patient Registry examined pro-
ductivity losses in both patients (see below) and their
partners, defined as an adult cohabitee, irrespective
of gender. This approach is possible in Denmark as
labor market income is registered in central databases
that include all citizens.
Ultimately, the choice of method and assumptions
used to value informal care can lead to striking vari-
ability in cost estimates. For example, using the same
cohort of patients, annual informal caregiving was
valued at US$13,188 using the replacement costs
approach but was valued at US$27,789 using the
opportunity cost approach [3]. Similarly, a study from
Sweden found that informal costs can range from
SEK 60 billion to SEK 124 billion depending on the
approach used [69]. A systematic review conducted
by ADI indicated that the proportion of total disease
costs attributed to informal care ranged from 19% to
91% across studies, largely due to differences in the
assumptions and approaches used to assess and value
informal care [70]. ADI favors the use of the oppor-
tunity cost method [9, 50, 70], and while no clear
consensus has emerged in the published literature,
several reports have prudently presented results using
multiple approaches, typically as part of sensitivity
analyses [8, 25, 26, 46, 47, 59, 61, 71–74].
Patients: Productivity losses
It has been noted that productivity losses in patients
are generally less relevant in the context of ADRD,
since most of those affected are older people who
would in most cases be retired [50, 75]. Nonetheless,
productivity losses in patients have been assessed in
several studies. However, it is challenging to conclu-
sively assess the scale of productivity losses given the
sensitivity of cost estimates on the approaches used.
For example, in a comprehensive cost of illness study
of moderate to severe dementia patients in fifteen
European Union member states, productivity losses,
including mortality and morbidity losses, accounted
for only D 2.2 billion (1%) of total costs. In this
study, morbidity losses were adjusted for the “fric-
tion period”, a 90-day period of employee’s absence
from work due to illness before he or she is replaced
Y.H. El-Hayek et al. / Assessing the Costs of Alzheimer’s Disease 329
by another worker. However, if morbidity losses were
calculated using a human capital approach, produc-
tivity losses rose dramatically to D 7.3 billion.
Productivity losses are also challenging to assess
and compare across different studies due to several
potential confounding factors such as differences
in stages of illness in the populations examined,
country-specific differences in labor marker wages
or differences in the methods used in calculating
costs. For example, one study estimated productivity
losses due to premature mortality from AD based on
US death certificates from 1999 to 2010 [76]. Using
a human capital approach, the cost due to premature
mortality was $4.4 billion (2010 US dollars) over
the period 1999 to 2010 [76]. While non-trivial,
this pales in comparison to the total cost of ADRD,
which has been estimated at US$259 billion in
the US in 2016 alone [77]. Another report using
registry data from the Swedish Social Insurance
Agency estimated productivity losses in individuals
who were prematurely retired or on sick leave due
to a dementia diagnosis [69]. At SEK118 million
(2012), the productivity losses due to premature
retirement or sick leave in Sweden represented only
a minor component of total costs. A Danish study
examined productivity losses in 78,715 patients and
312,813 matched controls up to 10 years prior to
diagnosis [22]. In contrast to the above-mentioned
studies, productivity losses due to forgone wages in
patients comprised 18% to 36% of total per patient
costs (Percentages are based on our calculations
using the authors’ reported raw costs. In that study
total costs were defined as the sum outpatient and
inpatient costs, medication, public health Insurance,
and indirect costs such as foregone earnings) [22].
Commentary
The indirect costs of ADRD, in both patients and
caregivers, become increasingly elevated years
prior to a diagnosis of dementia
For example, in a Danish Study [22], employ-
ment rates and income from employment were lower
in patients than in matched controls up to 10 years
before diagnosis. Strikingly, partners of patients also
had a lower employment rate and income than those
in their control group, but this difference diminished
after diagnosis.
Informal costs of caring for community-dwelling
ADRD patients increase with disease severity
Most studies have assessed informal care costs as
a consequence of caring for a patient diagnosed with
dementia. Many studies of community-based patients
have further segregated individuals according dis-
ease severity (e.g., mild, moderate, severe), typically
based on measures such as Mini–Mental State Exam-
ination criteria or the Clinical Dementia Rating [8, 25,
56, 57, 59, 60, 71, 72, 74, 78, 79]. Despite the vari-
abilities in informal care cost estimates, several cross-
sectional and longitudinal studies have demonstrated
a direct association between costs and disease sever-
ity [25, 57, 59, 60, 78]. For instance, a longitudinal
study using the population-based community cohort
with dementia from the Cache County Study found
that informal costs increased by approximately 18%
per year, and that compared to very mild dementia,
informal costs increased over 2-fold for mild, 5-fold
for moderate and 6-fold for severe dementia [57, 80].
The total financial impact of ADRD on
households and the economy is substantial
A recent survey by the Alzheimer’s Association
found that many informal caregivers were forced
to cut back on expenditures on themselves and
their families to support a relative or friend with
ADRD. Notably, 20% of informal caregivers, includ-
ing 45% of spouses/partners and 17% of children,
reported having to spend money from their own retire-
ment savings [53]. Reduced savings can impact the
financial security not only of informal caregivers,
but potentially also of their children and succeed-
ing generations. Moreover, patients with MCI and
dementia exhibit impairments in financial abilities
and decision-making [81, 82], leading to increased
vulnerability to financial exploitation and abuse,
which is commonly associated with diminished or
impaired mental capacities [83]. For example, True
Link Financial, a financial-services firm, estimated
annual losses in the US from financial abuse of
the elderly at US$36.48 billion each year, of which
US$16.99 billion is lost due to financial exploita-
tion specifically designed to take advantage of older
Americans [84]. Most approaches to value informal
care, such as the opportunity or replacement cost
methods, or productivity losses in patients, may not
fully capture the financial burden on households such
as reduced savings and therefore underestimate the
indirect costs of the disease.
INTANGIBLE COSTS
Intangible costs are non-material costs which are
not typically covered in economic analyses since they
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are better expressed in qualitative terms and do not
easily lend themselves to monetization. Intangible
costs apply to both patients and caregivers and stem
from the deterioration of social, psychological, and
physical domains of quality of life (QOL) (e.g., pain
and suffering, impact on activities, use of time, per-
sonal relationships, and family) and/or exacerbation
of comorbid illnesses. The economic translation of
intangible costs is generally absent from studies that
estimate the socioeconomic burden of ADRD [13].
Patients: Quality of life and quality-adjusted life
years
Predominately two related methodologies have
been used to evaluate the intangible costs for ADRD
patients: namely, qualitative assessment of QOL
through various scales and questionnaires and the
quality-adjusted life year (QALY) concept.
At least 15 different instruments have been used to
evaluate various domains of QOL or health-related
quality of life (HRQOL) in ADRD patients [33, 85,
86]. QOL has been assessed with generic instruments,
such as the EuroQol five-dimension questionnaire
(EQ-5D) and 36-item Short-Form, as well dementia-
specific instruments, such as the Quality of Life
in Alzheimer’s Disease (QOL-AD) and Dementia
Quality of Life questionnaire (DEMQOL). Both the
QOL-AD and DEMQOL have been shown to be reli-
able and valid in patients with mild to moderate
dementia and have been recommended as instru-
ments of choice to assess QOL in clinical trials
[33, 85]. QOL measures can also be combined with
AD-specific measures of symptoms, mental and/or
physical functioning as well as determination of co-
morbid illness to provide a more holistic view of
wellbeing and quality of life [55, 87]. Comorbidi-
ties are generally captured and rated using electronic
health record data and/or questionnaires (e.g., Charl-
son comorbidity index).
However, there are several practical challenges
that confound a comprehensive understanding of
QOL in patients with ADRD [85, 88]. For instance,
ADRD patients themselves may be unaware of the
disease or its impact, and often exhibit reduced
insight or ability to consistently assess wellbeing and
QOL as cognitive function declines; moreover, the
agreement between patient self-reported and care-
giver proxy measures varies across studies [4]. Such
confounding factors may contribute to the signif-
icant variability in reported QOL measures both
within and across studies. For example, in one multi-
center, longitudinal study in the UK, approximately
equal proportions of patients reported declines or
maintenance/improvements in QOL measures, with
no significant group level changes over 18 months
[88]. In contrast, group proxy ratings changed but
depended on the instrument used; for example, EQ-
5D proxy data suggested an overall decline, while
DEMQOL proxy data indicated an overall increase,
in quality of life. Establishing a clear relationship
between QOL and disease severity has also been
challenging [88]. For example, some studies have
shown that QOL declines for patients as the dis-
ease progresses [89–92], while others have found
no clear or consistent relationships between QOL
measures and disease severity [88, 93–95]. Please
see Box 3 for a summary of key findings from this
section.
Box 3: Intangible Costs—Key Takeaways
• Intangible costs in patients and caregivers
have primarily been assessed using instru-
ments that evaluate QOL in patients and
caregivers; QALYs are commonly used in
cost-effectiveness (or cost-utility) studies.
• Variability in the directionality of QOL
changes both within and across studies has
been noted. For example, some studies have
shown that QOL declines for patients as the
disease progresses, while others have found
no clear or consistent relationship. Simi-
larly, caregivers can experience both a rise
or decline in QOL in response to caring for a
person with ADRD.
• Challenges in quantifying the impact of
ADRD on QOL may have important impli-
cations for the allocation of resources
or reimbursement decisions. For example,
different methodologies used to calculate
QALYs may lead to contrasting results with
respect to the cost-effectiveness of health
interventions.
• Methodological limitations aside, several
studies have shown a strong correlation
between caregiving and health status of the
caregiver; moreover, the subjective burden
experienced by informal caregivers generally
increases with disease severity.
• Notably, both QOL and caregiver burden may
be impacted several years before the onset of
dementia.
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The challenges in assessing QOL in ADRD may
have important implications for the allocation of
resources or reimbursement decisions, since the
impact of interventions on QOL are increasingly
being adopted in health technology assessments
in several countries (e.g., UK, Canada, Sweden,
Germany) [86, 96]. One specific metric that is com-
monly used in cost-effectiveness (or cost-utility)
studies is the QALY [96, 97], which aims to combine
mortality and morbidity into a single measurement.
QALYs aim to quantify the impact of an intervention
on both length of life and HRQOL. The use of QALYs
in health economic assessments of interventions for
ADRD, however, is controversial and challenging [5,
96, 98].
While numerous studies have assessed QOL in
ADRD, relatively fewer have translated their find-
ings into the health utility or health state values that
are required for QALY calculations (see Box 4) [96].
Several QOL instruments such as the EQ-5D and
DEMQOL have been used to quantify health utility
weights in ADRD patients. Health utility values tend
to decline with advancing disease severity, but a range
of results have been reported within disease stages:
mild AD (0.52–0.73); moderate AD (0.30–0.53);
severe AD (0.12–0.49) [96]. Moreover, based on
a recent meta-regression analysis [86], health state
values can vary according to whether they rely on
self-reported versus proxy data, the type of instru-
ment used, and the modes of administration (e.g.,
face-to-face interview, survey, or phone interview).
The authors of that study concluded that different
approaches to assess utility values can result in signif-
icant differences in QALYs and may therefore lead to
Box 4: QALYs and Health States
The concept underlying a QALY is that patients
move through ‘health states’ over time, with each
health state having a value. QALYs are there-
fore calculated by multiplying the duration of time
spent in a health state by the HRQOL weight (or
utility) associated with that health state. Weights
are measured on a scale of 0 to 1, where 0 indi-
cates death and 1 indicates best possible health.
Negative values indicate health states worse than
death. Weights can be generated by either direct
or generic preference-based measures. The lat-
ter includes questionnaires such as the EuroQol
(EQ)-5D, Short Form 6D, and the Health Utilities
Index.
contrasting results on the cost-effectiveness of health
interventions.
Caregivers: Quality of life and caregiving burden
Caregiver QOL is evaluated using approaches sim-
ilar to those used for patients, and in some cases the
same scales can be applied to both caregivers and
patients (e.g., EuroQoL, Short-Form Health Survey).
However, more specific assessments (e.g., Care-
Related QOL, Caregivers’ QOL Index) have been
developed to capture various dimensions unique to
caregiver QOL [29]. The QOL of ADRD caregivers
is a complex construct and is influenced by several
factors [95]. For example, studies have shown that
caregivers can experience both a rise or decline in
QOL in response to caring for a person with ADRD.
Improvements in QOL have been attributed to many
factors such as a positive sense of accomplishment
or strengthened family ties; deteriorations have been
tied to the negative emotional, social, financial, or
physical burden associated with caring for a person
with ADRD. There is consensus that more sensi-
tive instruments are needed to measure the QOL
associated with caregiving for ADRD patients [4,
95].
Measures of caregiver ‘burden’ evaluate the tasks
required to provide caregiving (objective burden) and
the caregiver’s perception on the degree to which
caregiving has affected emotional, financial, physi-
cal and social functioning (subjective burden). The
Zarit Burden Interview (ZBI) is one of the most com-
monly used scales to assess the subjective burden
experienced by informal ADRD caregivers [24, 26,
74, 91, 99]. Similarly, the Caregiver Burden Inven-
tory, among other instruments (e.g., Role Overload
Scale, Caregiver Strain Index), have also been com-
monly used to measure the subjective and objective
aspects of caregiver burden [29, 30, 56, 100]. As with
patients, the Charlson comorbidity index is used to
assess comorbid conditions in caregivers; however,
there are numerous other instruments used in pop-
ulations studies to gauge related aspects of health in
caregivers, including depression (e.g., Center for Epi-
demiologic Studies Depression Scale), anxiety (e.g.,
Generalized Anxiety Disorder scale), mood (e.g.,
Positive and Negative Affect Scale), and sleep quality
(e.g., Pittsburgh Sleep Quality Index) among others
[29, 30, 101–103]. There is no clear consensus on the
most appropriate instrument to use to gauge caregiver
health status.
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Commentary
Figure 1 provides a depiction that represents the
total burden of ADRD as not only measured soci-
etal costs but also hidden costs that, together with
measured costs, represent a total burden that is much
greater in magnitude and duration than is currently
accurately assessed and appreciated.
The intangible costs of ADRD appear to exist
years before the onset of dementia
Patients with subjective cognitive decline and MCI
show a decline in almost every dimension of HRQOL
compared with matched controls [104, 105]. Addi-
tionally, patients with MCI also contend with an
increased risk of mortality [106]. Similarly, care-
giver burden also extends before ADRD symptom
onset in caregivers of patients with MCI—depression
and psychological comorbidity, although not as pro-
nounced as in dementia caregivers, are common
complications [107].
Informal caregiver burden increases over time
and with disease severity
Several studies in community-dwelling ADRD
patients have shown that caregiver burden, as
measured with the ZBI questionnaire and other
approaches, generally increases with disease severity,
being directly related to patient functional abili-
ties and level of dependence on the caregiver [91,
108, 109]. However, the link between caregiver
QOL and the severity of dementia is currently
unclear.
Informal caregivers report poorer health status
and greater comorbid disease risk compared
with non-caregivers
Several studies have demonstrated a strong
correlation between caregiving and health status
of the caregiver [29–31, 55, 99–102, 110–116].
For example, based on data from Brazil’s National
Health and Wellness Survey, caregiving was asso-
ciated with significantly increased risk of depressive
Fig. 1. Tip of the iceberg: Measured societal costs represent only a proportion of the total burden of ADRD. Most studies that have assessed
the costs of ADRD have focused on patients with a dementia diagnosis and have generally demonstrated that costs increase with disease
severity. However, such studies may not fully capture the total impact of ADRD for three reasons. First, the magnitude of indirect costs
(e.g., lost productivity, informal caregiving) can vary widely depending on the methodologies and assumptions used. Second, cost of illness
studies may not be measuring the full spectrum ADRD costs; for example, financial impacts on households (e.g., reduced savings, financial
exploitation, out of pocket costs, unemployment) may have substantial and intergenerational effects on the economy. Finally, some studies
suggest that costs begin to accrue years before a dementia diagnosis, albeit at a comparatively lower rate than those in advanced disease
stages. However, given the long preclinical stage (estimated at 10–20 years), it is possible that these ‘hidden costs’ represent a substantial
fraction of cumulative ADRD costs. Given the current evidence base, we cannot accurately gauge the size of these ‘hidden costs’, making it
challenging to quantify the full burden of ADRD and the potential value of health interventions and policies.
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symptoms, anxiety, insomnia, hypertension, pain,
and diabetes [87]. Similarly, a recent systematic
review and meta-analysis found that the prevalence
of depression among caregivers was 34.0%, anxiety
43.6%, and use of psychotropic drugs 27.2%, with
increased probability of depression in female and
spousal caregivers [110]. Notably, female caregivers
of ADRD patients are more likely to develop
depression than male caregivers [110, 117]. The
U.S. Alzheimer’s Association recently estimated
the physical and emotional impact of dementia
caregiving to have resulted in US$11.8 billion in
health care costs in the U.S. in 2018 [6].
CONCLUSIONS, RECOMMENDATIONS,
AND OUTLOOK
The magnitude and complexity of the socioeco-
nomic costs of ADRD are staggering and rapidly
increasing. Moreover, despite improvements in the
quality of care for patients and the identifica-
tion of several potentially modifiable risk factors
[118], the causal mechanisms of ADRD are com-
plex, multifactorial and not fully elucidated, and no
disease-modifying intervention is available to delay,
halt, or reverse the underlying pathology. Approved
symptomatic treatments for AD (i.e., cholinesterase
inhibitors and memantine), on average modestly
improve or stabilize dementia-related cognitive and
behavioral symptoms over short intervals of 6–12
months, and mitigate inevitable clinical decline over
the course of several years [119–122]. Driven by
greying populations across the globe, unrelenting
growth in the prevalence of ADRD will therefore only
magnify the human, societal, and economic burden
of the disease—potentially overwhelming increas-
ingly fragile support systems beyond the threshold
of sustainability.
It is widely acknowledged that immediate pol-
icy action is necessary to curb the growing burden
of ADRD in tandem with the ongoing efforts to
develop more efficacious treatments or a prevention
[4, 5, 123–125]. Success will require all stake-
holders, including policymakers, healthcare industry
leaders, advocacy groups, societies and associa-
tions, academia, biopharma, payers, clinicians, and
researchers, to work shoulder-to-shoulder to address
roadblocks that are hindering our understanding of
the scope, scale and nature of the costs of ADRD so
that we can develop, assess, and prioritize effective,
evidence-based policies, strategies, and interventions
to meet this growing global health crisis.
First, care for people with ADRD is provided by
several sectors in society—with social care systems
(e.g., long-term care and home services) and infor-
mal caregivers shouldering the greatest burden—and
it is therefore difficult to isolate which sector is
absorbing which costs. For example, most studies
assessing direct costs of ADRD typically focus on the
type of cost and generally do not distinguish which
stakeholder absorbs the cost. Additionally, regions
vary in the way that resources (and associated costs)
are classified as belonging to the healthcare and/or
social care systems, further complicating the task
of delineating which stakeholder will shoulder the
cost [22, 26, 38]. An added level of complexity in
the ADRD arena is that informal care time could
be framed or absorbed in diverse ways. For exam-
ple, informal care could be viewed as an indirect cost
absorbed by households (e.g., lost wages); however,
if informal care is replaced by professional (paid)
caregivers, it becomes a cost to health systems (or
insurers), and paradoxically, a potential stimulus to
the economy given that new jobs would be created.
Second, despite general agreement that indirect
costs form a significant component of the total costs
of ADRD, the quantification of these costs is prob-
lematic. Wide variability in cost estimates has been
observed for informal care costs as well as productiv-
ity losses in patients, potentially due to differences in
the methodologies used or study design. Furthermore,
common approaches to valuing indirect costs may not
fully capture other financial impacts on households,
such as reduced expenditures or savings.
Third, a potentially massive component of the total
cost of AD is ‘hidden’: symptoms and sequelae of
the disease usually begin to manifest years, if not a
decade, before diagnosis (see Fig. 2 for a concep-
tualized synthesis of the magnitude of costs borne
by key stakeholders at different stages of disease).
In the new National Institute on Aging-Alzheimer’s
Association (NIA-AA) AD Research Framework,
AD is conceptualized pathobiologically on a patho-
logical continuum measured by core biomarkers
relating to abnormal amyloid, tau, and neurodegen-
eration, as opposed to being characterized by clinical
symptoms relating to increasing severity of cognitive
and functional deficits as well as behavioral changes
[19, 126, 127] (see Box 5). This shift in research
thinking is likely to eventually have critical impli-
cations for clinical care, and in how we measure
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Fig. 2. The cost of ADRD across the spectrum of the disease to
key stakeholders groups. The nature (i.e., direct, indirect, intan-
gible) and magnitude (i.e., low, medium, high) of ADRD costs
incurred by different stakeholders varies by the stage of disease
(i.e., preclinical, prodromal, mild, moderate, severe).
Box 5: The Evolving Definition of AD
AD has traditionally been defined based on
clinico-pathological criteria. However, based in
part on advances in the use of biomarkers,
a clinico-biological approach was adopted by
the International Work Group and recently by
the NIA-AA 2018 “Research Framework”. Both
approaches define AD biologically using biomark-
ers as proxies of neuropathology. Further, both
approaches acknowledge AD as a pathologic
continuum—a continuous process in both cogni-
tive and biomarker domains, that can be divided
into three clinical stages: a long preclinical period,
followed by a prodromal or MCI phase with
mild symptoms, and then dementia. However, the
main update in the NIA-AA’s 2018 Framework is
that cognitive impairment is now viewed, in the
research realm, as a symptom/sign of the disease
rather than a requirement for defining AD.
and assess the costs of the disease and the value
of potential interventions. For instance, while most
studies examining the costs of AD have focused on
patients with dementia, there is evidence that the bur-
den on patients, families and health systems may be
elevated many years prior to a dementia diagnosis.
This suggests that a sizable portion of the burden of
the disease could be hidden before dementia is clin-
ically diagnosed. Moreover, a biological definition
of AD based on biomarkers also raises the intrigu-
ing possibility of intervening at earlier stages of the
disease continuum. Indeed, several reports have sug-
gested that significant savings could be realized by
either slowing/delaying disease progression through
lifestyle modification [128–130] or promoting early
diagnosis [49].
Finally, since ADRD are chronic, progressive
disorders that often involve a decade or more of
increasing and wide-ranging effects, assessing the
full costs of disease and illness, or the full value of
potential diagnostics and interventions, is not feasible
during short-term studies involved in typical clini-
cal trials [4, 28, 131]. Policymakers and stakeholders
therefore need high-quality, long-term (ideally 5+
years), real-world data regarding disease progres-
sion rates, prevalence, costs, symptoms and clinical
outcomes across the ADRD continuum to estimate
future disease burden with confidence. However, such
data are lacking [4, 5, 28]. While several studies
have followed patients with ADRD longitudinally
for periods up to 20 years (e.g., English Longitu-
dinal Study on Aging, Swedish National Study on
Aging) and may supply some of these data, these
studies have generally been focused on patients with
a dementia diagnosis and rely on a limited range of
assessments [4, 28]. One recently launched industry-
sponsored observational cohort study, the Insights to
Model Alzheimer’s Progression in Real Life (initi-
ated in January 2019) [132], aims to assess the clinical
meaningfulness of selected cognitive test scores that
may track changes along the spectrum of preclinical
AD, prodromal AD/MCI due to AD, and dementia
due to AD, and to gather 5-years of longitudinal data
on mortality, institutionalization, dependence, costs,
caregiver burden, and QOL.
The potential impact of research efforts to
assess the long-term utility and costs of diag-
nostics and interventions in real-world clinical
settings, while still lacking, is supported by recent
preliminary results of shorter-term studies with quasi-
experimental (case-control) designs. For example,
the IDEAS Study in the U.S. is one recent attempt
to measure the clinical value of new diagnostics
by looking at approximately 18,500 Medicare ben-
eficiaries aged 65 years and older with MCI or
dementia in which etiological diagnosis was found
to be in doubt by a dementia specialist in order
to assess the clinical impact of amyloid- PET
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scans on patient outcomes, treatments and costs. In
this study, the US Centers for Medicare and Med-
icaid Services utilized the Coverage with Evidence
Development mechanism to assess whether obtain-
ing an amyloid- PET scan may lead to substantial
changes in short-term, 90-day diagnosis and man-
agement, and in intermediate-term, 12-month clinical
events (e.g., hospitalizations, emergency department
visits, testing) and direct costs. The recently pub-
lished results of the 90-day outcomes support that
amyloid PET results significantly changed both the
clinical diagnosis (from AD to non-AD disease in
25%, and from non-AD to AD disease in 10%)
and the composite outcome of clinical management
(e.g., medications, counseling, additional testing) (in
60–63%) [133]—results that are consistent with the
ABIDE study performed in 507 patients seen at
two dementia specialty centers in the Netherlands
[134].
While it is inherently challenging, due to practical
considerations, to demonstrate significant short-term
cost savings associated with “earlier” timely and
accurate diagnosis of CID, if paired with appropri-
ate care, it is a face-valid proposition that outcomes
should be improved and “total” costs mitigated. An
example of research that aims to address the latter
regarding direct costs is from a recently published
real-world quasi-experimental case-control interven-
tional study, involving more than 1,000 Medicare
beneficiaries (and 2,100 database controls) aged 65
and older, that assessed the utility of a 3-year compre-
hensive dementia clinical care intervention program
that consisted of structured needs assessments of
patients and their caregivers, implementation of indi-
vidualized care plans with input from primary care
physicians, monitoring and revising care plans, refer-
ral to community organizations for dementia-related
services and support, and access to a clinician for
assistance and advice 24 hours per day, 7 days per
week. This study found a reduction of admissions
to long-term care facilities and an average direct
cost savings of US$284 per participant per quarter
(equivalent to US$1,136 per year) [135]. Other inter-
ventional, care coordination, and real-world studies
of care ecosystems are underway [136] and will be
needed to provide the evidence-base to support the
face validity that timely CID diagnosis and coor-
dinated comprehensive support and care not only
improve short- and long-term outcomes but also lead
to longer term total cost savings.
In summary, the overall lack of up-to-date, compre-
hensive, and long-term “clinical effectiveness” data
regarding real-world clinical outcomes and progres-
sion, and which also relate these outcomes to costs,
burden, and impact parameters, constitute a major
limitation of pharmacoeconomic models (e.g., deci-
sion analytical models) currently used at the policy
level to quantify the effects of diagnostics and inter-
ventions for ADRD. Many such models have been
informed by small sample sizes or are outdated;
these include, for example, recent health technology
appraisals of cholinesterase inhibitors and meman-
tine by the National Institute for Health and Care
Excellence (NICE) in the UK [28, 98].
Recommendations
It is evident that no single stakeholder can solve
all the scientific, health system, and public health
challenges related to ADRD experimental therapeu-
tics, clinical care, prevention, and health care delivery
alone. Such a complex problem requires solutions
that involve collective commitment, collaboration,
investment, and effort. Therefore, in line with rec-
ommendations from international groups and thought
leaders [118, 123, 137–141], there is an urgent need
for integrated and innovative approaches to measure,
manage and mitigate the burden of AD by:
• Developing and implementing better tools, mea-
sures, and programs to more accurately assess
the real-world costs of ADRD. For example,
leveraging new technologies such as wearables
and apps to more frequently and accurately mea-
sure the time and burden of caregiving-related
activities (e.g., on a daily basis as opposed to
retrospective reports of previous 30 days or sev-
eral months as used by current questionnaires),
or to quantify the frequency, duration, and nature
of resource utilization. Such data could then be
directly linked to actual costs incurred via elec-
tronic health records billing, and pharmacy and
insurance databases (e.g., in Medicare patients).
• Establishing pre-competitive investments in
real-world population observational studies and
registries across the continuum of aging, cog-
nitive impairment, and dementia to examine
the relationships between cognitive aging, co-
morbidities, and ADRD progression and costs
across the totality of the aging, clinical syn-
dromic, and disease spectrums. Also supporting
real-world quasi-experimental and, when eth-
ically possible, experimental studies to assess
the clinical impact and long-term costs and ben-
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efits related to establishing and implementing
best clinical practices [142] to improve timely
diagnosis, disclosure, treatments, and care inter-
ventions in the CID spectrum due to ADRD.
• Establishing a better understanding of which
stakeholder is ultimately absorbing the
costs—whether health systems, insurers, social
systems, employers, families or patients—to
inform coordinated funding mechanisms for
interventions and care paradigms that reflect
all impacted “payers” and deliver greater value
to patients, caregivers and their families (see
Fig. 2).
• Building on an improved understanding of
ADRD costs to develop more accurate cost-
of-illness frameworks and forecasting models
attuned to the socioeconomic realities of ADRD
in order to support rational resource allocations
and investment decisions.
• Investing and preparing for the advent of
biomarker-based tests that can help accurately
identify the hallmarks of ADRD and the con-
tributions of multiple pathologies to clinical
symptoms and CID, to improve provision of
a timely diagnosis and to better inform prog-
nosis and effects of early intervention and
care. For example, fluid-based biomarkers, from
blood and cerebrospinal fluid, and neuroimag-
ing markers that could be employed in the use
of potential future disease modifying therapies
[122], which may have greatest impact at the
earliest stages of disease, in order to select appro-
priate patients, and to monitor for safety and
therapeutic effects.
• Ensuring that the assessment of the value of
new treatment, management and care meth-
ods, whether care interventions, symptomatic
treatments or disease modifying therapies for
ADRD, account for their ‘full value’—including
their potential to alleviate direct, indirect and
intangible costs affecting the broad spectrum of
stakeholders impacted by the disease.
Outlook
Driven by greying populations across the globe,
the costs of ADRD are predicted to become unsus-
tainable. Although there is no cure, there is growing
optimism that symptomatic stages of ADRD may
be preventable or mitigated through a multi-pronged
combination of risk factor reduction, early detection,
novel therapeutics, and integrated care and support
paradigms. A bold vision of a world in which ADRD
is preventable and where patients and caregivers can
receive the care and support needed to preserve a life
of dignity and meaning was recently ratified at the
70th World Health Assembly, where member states
endorsed an unprecedented global action plan on the
public health response to dementia [123]. However,
a centrally emergent theme from this review is that
it is challenging to gauge the true value of poli-
cies, programs or interventions in the ADRD arena
given the long-term, progressive nature of the dis-
ease, its insidious socioeconomic impact beyond the
patient and the formal healthcare system, and the
complexities and current deficiencies (in measures
and real-world data) in accurately calculating the full
costs to society. By extension, such challenges can
obfuscate decision-making on the effective alloca-
tion of funds and resources across healthcare, social
care and other relevant sectors. There is therefore an
urgent need for all stakeholders to establish a com-
mon understanding of the challenges in evaluating the
full cost of ADRD and define approaches that allow us
to measure these costs more accurately, with a view
to prioritizing evidence-based solutions to mitigate
this looming public health crises.
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